226 related articles for article (PubMed ID: 18936688)
1. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
Hilson JB; Schnitt SJ; Collins LC
Am J Surg Pathol; 2009 Feb; 33(2):227-32. PubMed ID: 18936688
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast.
Hilson JB; Schnitt SJ; Collins LC
Am J Surg Pathol; 2010 Jun; 34(6):896-900. PubMed ID: 20463570
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
4. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
[TBL] [Abstract][Full Text] [Related]
5. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas.
Popnikolov NK; Ayala AG; Graves K; Gatalica Z
Am J Clin Pathol; 2003 Aug; 120(2):161-7. PubMed ID: 12931544
[TBL] [Abstract][Full Text] [Related]
6. High-grade carcinomas of the breast showing patterns of mixed ductal and myoepithelial differentiation (including myoepithelial cell-rich carcinoma of the breast).
Coyne JD; Dervan PA; Barr L
Histopathology; 2004 Jun; 44(6):580-4. PubMed ID: 15186273
[TBL] [Abstract][Full Text] [Related]
7. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Rabban JT; Koerner FC; Lerwill MF
Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
[TBL] [Abstract][Full Text] [Related]
8. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
Rabban JT; Chen YY
Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
[TBL] [Abstract][Full Text] [Related]
9. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
10. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
[TBL] [Abstract][Full Text] [Related]
11. Ductal carcinoma in situ with spindle cells: a potential diagnostic pitfall in the evaluation of breast lesions.
Tan PH; Lui GG; Chiang G; Yap WM; Poh WT; Bay BH
Histopathology; 2004 Oct; 45(4):343-51. PubMed ID: 15469472
[TBL] [Abstract][Full Text] [Related]
12. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells.
Rohilla M; Bal A; Singh G; Joshi K
Clin Breast Cancer; 2015 Oct; 15(5):335-42. PubMed ID: 25700939
[TBL] [Abstract][Full Text] [Related]
14. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function.
Sarper M; Allen MD; Gomm J; Haywood L; Decock J; Thirkettle S; Ustaoglu A; Sarker SJ; Marshall J; Edwards DR; Jones JL
Breast Cancer Res; 2017 Mar; 19(1):33. PubMed ID: 28330493
[TBL] [Abstract][Full Text] [Related]
15. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium.
Moinfar F; Man YG; Bratthauer GL; Ratschek M; Tavassoli FA
Cancer; 2000 May; 88(9):2072-81. PubMed ID: 10813719
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
17. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain.
Kalof AN; Tam D; Beatty B; Cooper K
J Clin Pathol; 2004 Jun; 57(6):625-9. PubMed ID: 15166269
[TBL] [Abstract][Full Text] [Related]
18. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Wykoff CC; Beasley N; Watson PH; Campo L; Chia SK; English R; Pastorek J; Sly WS; Ratcliffe P; Harris AL
Am J Pathol; 2001 Mar; 158(3):1011-9. PubMed ID: 11238049
[TBL] [Abstract][Full Text] [Related]
19. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.
Nielsen BS; Rank F; López JM; Balbin M; Vizoso F; Lund LR; Danø K; López-Otín C
Cancer Res; 2001 Oct; 61(19):7091-100. PubMed ID: 11585740
[TBL] [Abstract][Full Text] [Related]
20. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
